Glenmark Pharmaceuticals has received final approval from the US Food & Drug Administration (FDA) for its nystatin and triamcinolone acetonide cream (100,000 units per gm and 1 mg per gm) - a generic version of Mycolog-II cream of Delcor Asset Corporation.
Mycolog-II, which is no loger being marketed in the US, is indicated for the treatment of cutaneous candidiasis (a fungal infection of skin).
According to IMS Health sales data for the 12 months period ending August 2016, the Mycolog-II cream market (which includes brand and all available therapeutic equivalents) achieved annual sales of approximately $ 120.9 million.
Glenmark's current porfolio consists of 111 products authorised for distribution in the US marketplace and 60 ANDAs pending approval with the US FDA.
Mycolog-II, which is no loger being marketed in the US, is indicated for the treatment of cutaneous candidiasis (a fungal infection of skin).
According to IMS Health sales data for the 12 months period ending August 2016, the Mycolog-II cream market (which includes brand and all available therapeutic equivalents) achieved annual sales of approximately $ 120.9 million.
Glenmark's current porfolio consists of 111 products authorised for distribution in the US marketplace and 60 ANDAs pending approval with the US FDA.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%